A note on this column: This article is general medical information, not a description of a service offered at this practice. Dr. Ishiguro's surgical practice is focused on adult hip and knee conditions — he does not treat Osgood-Schlatter disease, a growth-related condition of the pediatric and adolescent skeleton. This column is written to help parents and young patients understand a very common condition and know when and how to seek the right specialist, typically a pediatric orthopedist or sports medicine physician.

What Osgood-Schlatter disease actually is

Osgood-Schlatter disease (OSD) is not a disease in the infectious sense — it's a traction injury at the growth plate. The patellar tendon, which runs from the kneecap down to the shin bone, attaches at a bony bump called the tibial tuberosity. In growing children and adolescents, this attachment point is still made partly of soft, developing cartilage (an apophysis) rather than fully hardened bone. Repetitive pulling from running and jumping can irritate and inflame this growth center, causing pain, swelling, and — over time — a visible, sometimes permanent bony prominence below the kneecap.

It's classified as an overuse "apophysitis," in the same family of conditions as Sever's disease of the heel or Sinding-Larsen-Johansson syndrome at the lower pole of the kneecap. It occurs specifically during the adolescent growth spurt, when bones lengthen faster than the surrounding muscles and tendons can comfortably stretch to keep pace, increasing tension at the tendon attachment.

Who gets it — and how common it is

OSD is genuinely common. A population-based study of 956 Brazilian adolescents aged 12 to 15, examined regardless of whether they had symptoms, found a prevalence of 9.8% overall — 11.0% in boys and 8.3% in girls (de Lucena et al., Am J Sports Med, 2011). Among athletic adolescents specifically, other studies have reported figures as high as 21%, compared with roughly 4.5% in non-athletic peers of the same age, underscoring how strongly the condition tracks with sports participation involving running and jumping — basketball, football (soccer), volleyball, and athletics among the most frequently implicated.

What the evidence shows: A retrospective cohort study using electronic health records from over 200,000 general-practice patients in the Netherlands found the incidence of newly diagnosed OSD to be 3.8 per 1,000 person-years in children and adolescents aged 8 to 18 (95% CI, 3.5–4.2). Boys had nearly double the incidence of girls (4.9 vs. 2.7 per 1,000 person-years), and peak incidence occurred at age 12 in boys and age 11 in girls — consistent with the earlier average growth spurt in girls (van Leeuwen et al., Br J Gen Pract, 2022).

The age pattern reflects the underlying biology: symptoms typically begin during the growth spurt, around ages 10–15 in boys and 8–13 in girls, and the condition affects both knees in an estimated 20–30% of patients, though usually not with identical severity or timing on each side.

Symptoms

The hallmark complaint is pain localized precisely over the tibial tuberosity — the bony bump below the kneecap — rather than diffuse knee pain. It's typically activity-related: worse with running, jumping, squatting, climbing stairs, or kneeling directly on the area, and eased by rest. Over weeks to months, many patients and parents notice the bump itself becoming more prominent, sometimes accompanied by mild swelling and tenderness to direct pressure. Unlike many other knee problems in this age group, OSD does not typically cause the knee to lock, give way, or swell diffusely within the joint — findings that, if present, point toward a different diagnosis and warrant separate evaluation.

How the diagnosis is made

OSD is primarily a clinical diagnosis, made from the characteristic history (an active, growing adolescent with focal pain at the tibial tuberosity that worsens with sport) and a physical exam showing tenderness and prominence at that exact spot, reproduced by resisted knee extension or direct pressure. Because the presentation is usually so typical, imaging is not required to confirm the diagnosis in straightforward cases.

Plain X-rays are still commonly obtained, less to make the diagnosis than to rule out other causes of anterior knee pain in this age group — a fracture, a bone tumor, or infection — particularly when the presentation is atypical, one-sided and acute rather than gradual, or accompanied by systemic symptoms like fever. Ultrasound can also demonstrate the swelling and irregularity at the tendon attachment and is useful in ambiguous cases or for tracking healing over time without radiation exposure.

Findings that should prompt a broader work-up, not just OSD management

What the evidence says about the natural course and treatment

The reassuring headline is that OSD is fundamentally a self-limiting condition: for most patients, symptoms resolve once the growth plate closes and the tibial tuberosity fully ossifies, typically by the mid-to-late teens. That said, "self-limiting" doesn't mean "ignore it" — a meaningful minority of patients, estimated in various studies at somewhere between 10% and 60%, report some persistent pain or discomfort with kneeling or sports into adulthood, even after skeletal maturity (Rhim et al., Diagnostics, 2025). That range is wide because study populations and follow-up periods vary considerably, but it's enough to justify taking the condition seriously rather than dismissing it as a purely cosmetic bump.

Commonly used first-line treatment measures

Important safety note: Corticosteroid injections, a common tool for tendon problems in adults, are specifically not recommended at the tibial tuberosity in children and adolescents because of the risk of growth plate injury and tendon weakening. This is a meaningful difference from how some adult tendinopathies are managed, and worth being aware of if an injection is ever suggested for a child's knee pain.

A real-world look at how OSD is actually managed in general practice — as opposed to how guidelines suggest it should be managed — found some interesting gaps.

What the evidence shows: In the Dutch general-practice cohort study, the most common management strategy was simple advice (55.1% of patients), followed by rest (21.0%), referral for imaging (19.5%), and physiotherapy (13.4%). The authors noted a discrepancy between this real-world pattern — particularly the relatively frequent use of imaging and specialist referral — and formal Dutch primary-care guidelines, which generally support a clinical diagnosis and conservative management without routine imaging in typical cases (van Leeuwen et al., Br J Gen Pract, 2022).

For the subset of patients whose symptoms don't settle with standard conservative care — particularly older adolescent athletes wanting to return to sport, or adults with persistent symptoms after growth plate closure — injection-based options have been studied as a next step before considering surgery.

What the evidence shows: A 2025 systematic review and meta-analysis of hyperosmolar dextrose injection (a regenerative-medicine technique, sometimes called prolotherapy) pooled three randomized trials and one case series covering 166 patients. At three months, there was no statistically significant difference in patient-reported outcome improvement between dextrose injection and placebo (SMD 1.92, 95% CI −0.12 to 3.96). However, a pooled analysis of two trials in athletic adolescents found patients receiving dextrose injection were 2.11 times more likely to achieve a pain-free return to sport at three months (95% CI 1.12–3.98), and at one year, two trials showed greater patient-reported improvement with dextrose injection than placebo (SMD 1.09, 95% CI 0.62–1.56). No injection-related complications were reported across the included studies (Rhim et al., Diagnostics, 2025). The authors were careful to note the evidence base remains limited, and did not recommend the treatment routinely — but described it as a reasonable option to discuss for young athletes who haven't responded to first-line conservative measures.

Surgery is reserved for a small minority of cases: patients with fully closed growth plates whose pain and functional limitation persist despite an adequate trial of conservative treatment, sometimes related to a persistent loose ossicle (bone fragment) within the patellar tendon. A 2026 systematic review pooling 15 studies and 712 patients across nonoperative, injection-based, and surgical treatment groups found that surgical excision of a symptomatic ossicle or tuberosity smoothing achieved a return to normal daily activities in 79–100% of patients when performed for appropriately selected, skeletally mature patients — though complication rates in the surgical literature were also notably higher than in the nonoperative or injection groups, reported in five of six surgical studies at rates ranging from 0% to as high as 75.8%, including infection, hypertrophic scarring, and residual pain (Ndjonko et al., Orthop J Sports Med, 2026). This reinforces that surgery is a last resort after skeletal maturity, not an early-line option, and one best discussed carefully with a specialist given the wide range of reported outcomes.

When to see a specialist

Most cases of OSD can be managed with reassurance, activity modification, and simple home measures, ideally with guidance from a pediatrician, sports medicine physician, or physiotherapist. A referral to a pediatric orthopedic specialist is reasonable when pain is severe or worsening despite several weeks of conservative treatment, when the presentation is atypical (sudden onset, true joint swelling, night pain, or pain that isn't localized to the tibial tuberosity), when there's a suspected avulsion fracture after a sudden, sharp pain during activity, or when symptoms persist meaningfully into or beyond skeletal maturity. Because so many of the "watch and wait" recommendations depend on ruling out the less common but more serious alternatives, a single clinical evaluation at the outset — even for a condition this common — is worthwhile rather than assuming every case is straightforward.

References (PubMed / Journal)

de Lucena GL, dos Santos Gomes C, Guerra RO. Prevalence and associated factors of Osgood-Schlatter syndrome in a population-based sample of Brazilian adolescents. Am J Sports Med. 2011;39(2):415-420. DOI: 10.1177/0363546510383835

van Leeuwen GJ, de Schepper EIT, Rathleff MS, Bindels PJE, Bierma-Zeinstra SMA, van Middelkoop M. Incidence and management of Osgood-Schlatter disease in general practice: retrospective cohort study. Br J Gen Pract. 2022;72(717):e301-e306. DOI: 10.3399/BJGP.2021.0386

Rhim HC, Bjork LB, Shin J, Park J, DeLuca SE, McCarron KC, Jang KM, Ha C. Efficacy of Hyperosmolar Dextrose Injection for Osgood-Schlatter Disease: A Systematic Review with Meta-Analysis. Diagnostics (Basel). 2025;15(10):1282. DOI: 10.3390/diagnostics15101282

Ndjonko LCM, Klein JH, Chakraborty Y, Kata S, Alinda A, Abuelenein I, Kalluvila AT, Green DW, Fowowe O, Simpson S, Wooldridge T. Treatments for Osgood Schlatter Disease: A Systematic Review of the Literature. Orthop J Sports Med. 2026;14(3). DOI: 10.1177/23259671251387354